Clinical Trial Update: Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial of obatoclax with bortezomib in adults with aggressive relapsed or recurrent non-Hodgkin lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Obatoclax (obatoclax mesylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 1 | Status: TERMINATED